Ubs Group Ag Benitec Biopharma Inc. Transaction History

Ubs Group Ag

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.18 - $0.36 $166 - $333	-927 Reduced 72.76%	347 $0
Q4 2022 Feb 08, 2023	SELL	$0.13 - $5.95 $3,563 - $163,083	-27,409 Reduced 95.56%	1,274 $0
Q3 2022 Nov 10, 2022	BUY	$0.31 - $6.32 $5,197 - $105,967	16,767 Added 140.71%	28,683 $11,000
Q2 2022 Aug 10, 2022	BUY	$0.74 - $2.29 $8,561 - $26,493	11,569 Added 3334.01%	11,916 $13,000
Q1 2022 May 16, 2022	SELL	$1.96 - $2.96 $5,407 - $8,166	-2,759 Reduced 88.83%	347 $1,000
Q4 2021 Feb 14, 2022	BUY	$2.62 - $3.77 $5,357 - $7,709	2,045 Added 192.74%	3,106 $8,000
Q3 2021 Nov 15, 2021	BUY	$3.49 - $4.26 $2,641 - $3,224	757 Added 249.01%	1,061 $4,000
Q2 2021 Aug 13, 2021	SELL	$3.94 - $5.81 $4,519 - $6,664	-1,147 Reduced 79.05%	304 $1,000
Q1 2021 May 12, 2021	BUY	$2.59 - $9.26 $2,970 - $10,621	1,147 Added 377.3%	1,451 $8,000
Q3 2020 Nov 12, 2020	SELL	$5.66 - $8.7 $5,648 - $8,682	-998 Reduced 76.65%	304 $2,000
Q2 2020 Jul 31, 2020	BUY	$5.13 - $14.17 $6,679 - $18,449	1,302 New	1,302 $10,000

1.42M

Ticker BNTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,809,500
Market Cap $280M
Description
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.